U.S. National Institute of Health www.cancer.gov National Cancer Institute
National Cancer Institute
NCI Alliance for Nanotechnology in Cancer

Skip Header Links
About Programs News Resources Events Intranet Login
National Cancer Institute


NCI Alliance for
Nanotechnology in Cancer


Nanotech News

 

  Current Month

  News Archive

Monthly Features
News Releases
Alliance News
News Conferences

Sign-up Today


 
Back

Nanotech News


October 16, 2006

Nanoparticle Targets Cell Membranes, Triggers Cancer Cell Death

One of the unusual properties of tumor cells is that their cell membranes are more fluid and less rigid than those of normal cells. To take advantage of this difference in order to improve anticancer drug delivery, a team of investigators at Sojo University in Japan has developed a polymer-lipid hybrid nanoparticle that distinguishes between malignant and healthy cells.

Reporting their work in the journal Bioorganic and Medicinal Chemistry Letters, Ryuichi Ueoka, Ph.D., Pharm.D., and colleagues describe their work with a nanoparticle made by mixing two different nanoparticles and forcing them to fuse into one hybrid nanoparticle through the use of high frequency sound waves. When added to cultured cancer cells, these particles fuse with the tumor cell membrane. In contrast, these nanoparticles show only a slight ability to fuse with normal cells.

Nanoparticle fusion with malignant cells has a profound effect on cell viability. Soon after fusion, the cells begin producing enzymes that trigger programmed cell death, or apoptosis. Enzyme levels peak within one to two hours, triggering cell death. Given that this effect is seen with the nanoparticles themselves, these data suggest that using such nanoparticles to deliver antitumor drugs could have a profound killing effect on tumor malignant cells.

This work is detailed in a paper titled, “Membrane targeted chemotherapy with hybrid liposomes for colon tumor cells leading to apoptosis.” This paper was published online in advance of print publication. An abstract of this paper is available through PubMed.
View abstract.


A Service of the National Cancer Institute
National Cancer Institute Department of Health and Human Services National Institutes of Health FirstGov.gov Nanotechnology Characterization Lab Nanotechnology Teaming Portal